• A flunisolide-containing intranasal spray and matching placebo were used in an eight-week, double-blind parallel study in 67 patients with perennial rhinitis. Seventeen patients who did not benefit from treatment with the placebo then switched to flunisolide for a six-week open trial. Flunisolide-treated patients showed greater improvement in both duration and severity of symptoms, as well as a greater preference for flunisolide; 75% of patients either had "mild" symptoms or were asymptomatic and 67% stated that they experienced "substantial" or "total" control of symptoms. No serious side effects were encountered. Chief side effects in both drug and placebo groups were brief, mild, nasal burning and stinging on spray application. The drug exhibited no adverse effects on adrenal function (morning plasma cortisol levels).
(Arch Otolaryngol 105:649-653, 1979)
Sy RK. Flunisolide Intranasal Spray in the Treatment of Perennial Rhinitis. Arch Otolaryngol. 1979;105(11):649–653. doi:10.1001/archotol.1979.00790230019004
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.